An angel investor funds three startups with a total of $2 million. The botanical drug firm gets 40%, the gene therapy company 35%, and the synthetic biology lab the rest. The synthetic lab allocates 15% of its funding to safety testing. How much is spent on safety testing?

Thu, 07 May 2026 22:25:59 +0000

Angel Investor Funds Three Promising Startups with $2 Million—Synthetic Biology Lab Allocates $270,000 to Safety Testing A recent high-impact investment round highlights the growing momentum of innovative life science ventures, backed by an angel investor who committed a total of $2 million across three cutting-edge startups. The funding is strategically distributed to support early-stage development in transformative therapeutic areas. The investment portfolio includes:
- Botanical drug firm: 40% of $2M → $800,000
- Gene therapy company: 35% of $2M → $700,000
- Synthetic biology lab: Remaining 25% → $500,000 Notably, the synthetic biology lab is dedicating 15% of its $500,000 funding to rigorous safety testing—a critical step ensuring both regulatory compliance and long-term viability of its experimental technologies.